- Some patients taking SKYTROFA experienced mild injection-site reactions2
- Low immunogenicity, with no neutralizing antibodies detected1,2
- Only 6.3% (19 of 304) of patients showed detectable binding antibodies at any time1
AEs reported in ≥ 5% of SKYTROFA-treated pediatric patients and more frequently than in daily somatropin-treated pediatric patients (52 weeks of treatment)1
AEs | SKYTROFA (n = 105) |
Daily Somatropin (n = 56) |
---|---|---|
n (%) | n (%) | |
Viral infection | 16 (15%) | 6 (11%) |
Pyrexia | 16 (15%) | 5 (9%) |
Cough | 11 (11%) | 4 (7%) |
Nausea and vomiting | 11 (11%) | 4 (7%) |
Hemorrhage* | 7 (7%) | 1 (2%) |
Diarrhea | 6 (6%) | 3 (5%) |
Abdominal pain | 6 (6%) | 2 (4%) |
Arthralgia and arthritis† | 6 (6%) | 1 (2%) |

Efficacy and Safety Guide
Learn more about the clinical differentiation of SKYTROFA.